(NASDAQ: INVA) Innoviva's forecast annual revenue growth rate of 8.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.63%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.32%.
Innoviva's revenue in 2026 is $411,328,000.On average, 7 Wall Street analysts forecast INVA's revenue for 2026 to be $33,196,845,191, with the lowest INVA revenue forecast at $29,553,903,281, and the highest INVA revenue forecast at $36,507,937,168. On average, 7 Wall Street analysts forecast INVA's revenue for 2027 to be $37,396,080,183, with the lowest INVA revenue forecast at $30,514,638,470, and the highest INVA revenue forecast at $43,073,084,413.
In 2028, INVA is forecast to generate $38,690,146,779 in revenue, with the lowest revenue forecast at $32,996,846,347 and the highest revenue forecast at $44,301,966,200.